We are independent & ad-supported. We may earn a commission for purchases made through our links.
Advertiser Disclosure
Our website is an independent, advertising-supported platform. We provide our content free of charge to our readers, and to keep it that way, we rely on revenue generated through advertisements and affiliate partnerships. This means that when you click on certain links on our site and make a purchase, we may earn a commission. Learn more.
How We Make Money
We sustain our operations through affiliate commissions and advertising. If you click on an affiliate link and make a purchase, we may receive a commission from the merchant at no additional cost to you. We also display advertisements on our website, which help generate revenue to support our work and keep our content free for readers. Our editorial team operates independently of our advertising and affiliate partnerships to ensure that our content remains unbiased and focused on providing you with the best information and recommendations based on thorough research and honest evaluations. To remain transparent, we’ve provided a list of our current affiliate partners here.

How Was the Human Genome Sequenced?

Michael Anissimov
Updated Mar 03, 2024
Our promise to you
The Health Board is dedicated to creating trustworthy, high-quality content that always prioritizes transparency, integrity, and inclusivity above all else. Our ensure that our content creation and review process includes rigorous fact-checking, evidence-based, and continual updates to ensure accuracy and reliability.

Our Promise to you

Founded in 2002, our company has been a trusted resource for readers seeking informative and engaging content. Our dedication to quality remains unwavering—and will never change. We follow a strict editorial policy, ensuring that our content is authored by highly qualified professionals and edited by subject matter experts. This guarantees that everything we publish is objective, accurate, and trustworthy.

Over the years, we've refined our approach to cover a wide range of topics, providing readers with reliable and practical advice to enhance their knowledge and skills. That's why millions of readers turn to us each year. Join us in celebrating the joy of learning, guided by standards you can trust.

Editorial Standards

At The Health Board, we are committed to creating content that you can trust. Our editorial process is designed to ensure that every piece of content we publish is accurate, reliable, and informative.

Our team of experienced writers and editors follows a strict set of guidelines to ensure the highest quality content. We conduct thorough research, fact-check all information, and rely on credible sources to back up our claims. Our content is reviewed by subject-matter experts to ensure accuracy and clarity.

We believe in transparency and maintain editorial independence from our advertisers. Our team does not receive direct compensation from advertisers, allowing us to create unbiased content that prioritizes your interests.

The human genome was sequenced by two different groups in two different ways. The $3 billion US Dollar (USD) Human Genome Project (HGP), supported by the US Department of Energy, used a technique called "hierarchical shotgun sequencing", where it broke down the human genome into pieces consisting of 150,000 base pairs each. These pieces were then put inside bacteria where the bacteria's DNA replication machinery makes many copies of the sample for easier sequencing. These constructs are called bacterial artificial chromosomes. The project was founded in 1990 and took 13 years to complete, reaching its end in April 2003. A "rough draft" of the human genome became available in April 2000.

Another group, Celera Genomics, used a relatively novel approach called whole genome shotgun sequencing to sequence the human genome in much less time and at far lower cost ($300 million USD) than the federally-funded HGP. This group started in 1998 and finished in 2001. Whole shotgun sequencing involves breaking up multiple copies of the genome into smaller parts randomly, sequencing those parts, and then determining which parts connect up with which by seeing where the codons overlap. Supercomputing and sequencing algorithms contributed invaluably to the Celera approach, making it feasible. Prior to Celera's work, the largest genome sequenced through the whole shotgun approach was about 13 million base pairs, far short of the human genome's three billion base pairs. It is important to note that the Celera project did not start from scratch as the HGP did though; it was able to access existing information that had been previously published on GenBank, a collection of genetic sequences and data available to all.

Despite the human genome containing three billion base pairs, only 3 percent codes for proteins (the other 97 percent being junk DNA), creating a total of about 25,000 genes. This is small compared to estimates of 40,000 to 2,000,000 genes being tossed around prior to the completion of the project. The finiteness of the human genetic code means that it is feasible that one day, researchers be able to understand human genes in their entirety and even manipulate them.

Work continues on analyzing the work that came out of the HGP. The latest initiative is to find a way to sequence a human genome for less than $1,000 USD, which would make the technology feasible for wider use. A single sequencing could determine many important genetic characteristics of the person, including your likelihood of developing certain diseases. Craig Venter, former leader of the Celera project, has had his genome entirely sequenced and has spoken with various media outlets about the results and their implications.

The Health Board is dedicated to providing accurate and trustworthy information. We carefully select reputable sources and employ a rigorous fact-checking process to maintain the highest standards. To learn more about our commitment to accuracy, read our editorial process.
Link to Sources
Michael Anissimov
By Michael Anissimov
Michael Anissimov is a dedicated The Health Board contributor and brings his expertise in paleontology, physics, biology, astronomy, chemistry, and futurism to his articles. An avid blogger, Michael is deeply passionate about stem cell research, regenerative medicine, and life extension therapies. His professional experience includes work with the Methuselah Foundation, Singularity Institute for Artificial Intelligence, and Lifeboat Foundation, further showcasing his commitment to scientific advancement.
Discussion Comments
Michael Anissimov
Michael Anissimov
Michael Anissimov is a dedicated The Health Board contributor and brings his expertise in paleontology, physics, biology...
Learn more
The Health Board, in your inbox

Our latest articles, guides, and more, delivered daily.

The Health Board, in your inbox

Our latest articles, guides, and more, delivered daily.